SELLAS Life Sciences (SLS) Cash & Equivalents (2019 - 2024)
SELLAS Life Sciences (SLS) has disclosed Cash & Equivalents for 9 consecutive years, with $100000.0 as the latest value for Q3 2024.
- On a quarterly basis, Cash & Equivalents fell 97.5% to $100000.0 in Q3 2024 year-over-year; TTM through Sep 2024 was $100000.0, a 97.5% decrease, with the full-year FY2023 number at $100000.0, changed 0.0% from a year prior.
- Cash & Equivalents was $100000.0 for Q3 2024 at SELLAS Life Sciences, roughly flat from $100000.0 in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $35.3 million in Q4 2020 to a low of $100000.0 in Q1 2020.
- A 5-year average of $6.4 million and a median of $100000.0 in 2020 define the central range for Cash & Equivalents.
- Peak YoY movement for Cash & Equivalents: skyrocketed 35202.0% in 2020, then tumbled 99.72% in 2021.
- SELLAS Life Sciences' Cash & Equivalents stood at $35.3 million in 2020, then crashed by 99.72% to $100000.0 in 2021, then changed by 0.0% to $100000.0 in 2022, then changed by 0.0% to $100000.0 in 2023, then changed by 0.0% to $100000.0 in 2024.
- Per Business Quant, the three most recent readings for SLS's Cash & Equivalents are $100000.0 (Q3 2024), $100000.0 (Q2 2024), and $18.4 million (Q1 2024).